11/01/2023

Tempus Announces Eight Abstracts Accepted For Presentation at the 2023 Society for Immunotherapy of Cancer Annual Meeting

Tempus, a leader in artificial intelligence and precision medicine, today announced eight abstracts were accepted for presentation at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting, which convenes in San Diego, California, from November 1-5, 2023. 

“We continue to be a leader in the advancement of immunotherapy research, as evidenced by the abstracts we’re presenting this year,” said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. “We are making significant strides in advancing our own research initiatives while simultaneously supporting the therapeutic research efforts of our life science partners.”

This year, highlights of Tempus’ poster presentations include: 

  • Poster Presentation (34): Association of a novel circulating tumor fraction DNA biomarker of treatment response monitoring and clinical outcomes in a real-world, diverse pan-cancer cohort treated with immunotherapy
    • Session Date & Time: Saturday, Nov. 4, 2023; 9:00 a.m. – 8:30 p.m PST
    • Location: San Diego Convention Center; Exhibit Halls A and B1
    • Overview: This poster presents a novel approach for estimating circulating tumor DNA tumor fraction (ctDNA TF), ctDNA TF (denoted xF Monitor) utilizing diverse genomic events, and the association of changes in ctDNA TFs with ICI outcomes in a real-world pan-cancer cohort. xF Monitor is a novel serial quantitative ctDNA TF algorithm off the Tempus xF assay that has the potential to be used clinically as a predictive biomarker to stratify patients who may or may not be responding to ICI therapy.
  • Poster Presentation (158): Interrogating real world tumor-infiltrating T-cell repertoires to identify antigen enriched TCRs in a large pan-cancer clinical cohort
    • Session Date & Time: Saturday, Nov. 4, 2023; 9:00 a.m. – 8:30 p.m PST
    • Location: San Diego Convention Center; Exhibit Halls A and B1
    • Overview: In this study, we analyzed a large, real-world, clinicogenomic database to identify public T-cell receptor (TCR) repertoires associated with HLA-specific neoantigens and viral epitopes. The database includes over 130k patients with TCR data covering a diverse landscape of HLA genotypes and tumor neoantigens. By incorporating routine TCR repertoire profiling into a high-volume clinical genomic sequencing program, we have developed a rich, multi-modal resource for studying complex tumor-immune interactions. This dataset is a valuable resource for TCR therapeutic discovery, and can help identify naturally occurring TCRs that may minimize on-target, off-tumor toxicity.

 

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Related Content

View more
  • post image
    03/05/2025

    Evolving outcomes research: The convergence of data, technology, and collaboration

    This white paper offers an in-depth examination of the evolving field of outcomes research, focusing on the integration of real-world data and advanced analytics to improve patient outcomes. In it, we discuss the current state of the industry, the challenges of data standardization and quality, and the collaborative efforts shaping the future. Download to explore innovative approaches that are transforming outcomes research and driving the development of patient-centric healthcare solutions.

    Read more
  • post image
    02/24/2025

    Advancing precision medicine in the community setting with TIME and Next at Cancer and Blood Specialty Clinic

    Discover how Cancer and Blood Specialty Clinic, a community oncology network, utilized Tempus TIME to expedite clinical trial enrollment and is expanding their impact on patient care with Tempus Next, an AI-enabled care pathway platform.

    Read more
  • post image
    02/13/2025

    AI & ML in action: Real-time advances in precision medicine

    Explore the capabilities of the Tempus platform, where cutting-edge diagnostics meet actionable data insights to enhance precision medicine. Learn how AI and ML tools seamlessly integrate biomarkers into the diagnostic process, ensuring patients receive the right treatment(s) at the right time. Experience Tempus Lens in action, with an exclusive live demonstration of our newest AI advancements, and hear perspectives on AI's expanding role in healthcare and its transformative potential.

    Watch replay